China Resources Double-Crane Pharmaceutical Co Ltd
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From China Resources Double-Crane Pharmaceutical Co Ltd
Plus deals involving Zai Lab/Karuna, Zai Lab/Blueprint, Lotus/PharmaMar, Nippon Shinyaku/Dynacure, Alphamab/Ascletis, Aptose/Hanmi, Shanghai Pharmaceuticals/HUYABIO, KoBioLabs/SPH Sine, CURACLE/ Théa Open Innovation, Signet/XtalPi, Curi Bio/NEXEL, CANbridge/Scriptr and Ligand/CRDC.
While new oral COVID-19 drugs are commanding the headlines, a little-known Chinese biotech is pushing ahead with an intravenous small molecule antiviral candidate now moving towards Phase II/III US trials, its CEO tells Scrip.